AI is about to design custom therapies for every disease based on your DNA.

Every cell in your body has the exact same DNA—so how does a heart cell know to beat while an immune cell knows to fight an infection? 🧬✨

Google DeepMind just unveiled AlphaGenome 2, an AI breakthrough that zooms in from broad tissues down to single, individual cells to see how our DNA is actually read in real time.

Here is why this is a massive leap for medicine and biology:

🔬 Single-Cell Precision: Trained on over 107 million individual cells, it spots subtle genetic triggers inside specific cell types that older models missed.

⚡ Adapts on the Fly: Scientists can plug in data from just a few dozen cells from a brand-new lab experiment—like immune cells reacting to a vaccine or gut cells driving inflammation—and the AI adapts instantly with zero retraining.

🎯 Pinpointing Disease Drivers: It helps researchers trace complex genetic mutations directly to the exact cells causing diseases like IBD or severe COVID-19, paving the way for targeted, DNA-based therapies.

We are moving closer than ever to decoding the cellular instructions behind human health.

#ArtificialIntelligence #genomics #GoogleDeepMind #alphagenome2

Last year, we launched AlphaGenome to predict how DNA variants affect molecular activity across broad tissues. We expanded its reach with AlphaGenome Atlas, a platform containing predictions for all 9 billion possible single-letter changes in the human genome. These tools help researchers prioritize and interpret variant effects, driving discoveries in rare diseases, complex traits, and fundamental biology.

By zooming in from broad tissue averages to individual cell types and cell states, and redesigning the model’s architecture, AlphaGenome 2 represents a step-change improvement in variant predictive performance. Importantly, it allows researchers to predict variant effects in disease-relevant cells that would be missed in broad-tissue models, as well as predictions for cell and disease states that the model hasn’t seen before.

AlphaGenome 2 identifies nearly twice as many variants that change gene expression in cells, compared to our previous state-of-the-art model. Trained on more than 100 million individual cell profiles across 68 tissues, the model turns static cell atlases into a predictive engine for human genetics. AlphaGenome 2 is available today for non-commercial research via the AlphaGenome API, and in private preview for commercial research.